Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid Avoidance with EC-MPS in Renal Transplant
NCT00413920Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate sodium in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Number of Participants With the Occurrence of Treatment Failures at 6 Months Post-transplantation. Started Apr 2007; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00413920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413920.